Seropositive PLA2R-associated membranous nephropathy but biopsy-negative PLA2R staining

被引:13
作者
Luo, Jiao [1 ]
Zhang, Wang [1 ]
Su, Cailing [1 ]
Zhou, Zhanmei [1 ]
Wang, Guobao [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Natl Clin Res Ctr Kidney Dis, Renal Div,State Key Lab Organ Failure Res, Guangzhou, Peoples R China
关键词
PLA2R antibody; PLA2R antigen; PLA2R-associated MN; renal pathologic chronicity lesions; PHOSPHOLIPASE-A2 RECEPTOR AUTOANTIBODIES; ANTI-PLA(2)R AUTOANTIBODIES; GLOMERULAR DEPOSITS; KIDNEY BIOPSY; ANTIBODIES; DIAGNOSIS; ANTIGEN;
D O I
10.1093/ndt/gfaa239
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Serum phospholipase A2 receptor (PLA2R) anti-body (SAb) and glomerular deposits of PLA2R antigen (GAg) have been tested widely in idiopathic membranous nephropathy (MN). Recently, we noticed a special form of PLA2R-associated MN with positive circulating PLA2R antibody but negative PLA2R deposits in the glomeruli by immunofluorescence on frozen tissue (IF-F). The significance of this form of PLA2R-associated MN is yet to be elucidated. This study aimed to explore the clinicopathological features of these PLA2R-associated MN patients. Methods. This study enrolled 229 biopsy-proven PLA2R-associated MN patients with SAb+. SAb was measured by enzyme-linked immunosorbent assay, and GAg was detected by IF-F. These patients were divided into SAb+/GAg+ and SAb+/GAg- groups. Clinicopathological characteristics of SAb+/GAg+ and SAb+/GAg- PLA2R-associated MN patients were compared. PLA2R antigens of 19 SAb+/GAg- PLA2R-associated MN patients were verified by immunohistochemistry on paraffin tissue (IHC-P). Results. Among 229 SAb+ PLA2R-associated MN patients, 210 (91.70%) were GAg+ and 19 (8.3%) were GAg-. These 19 SAb+/GAg- PLA2R-associated MN patients presented positive PLA2R deposits by IHC-P. Compared with SAb+/GAg+ PLA2R-associated MN patients, SAb+/GAg- PLA2R-associated MN patients had higher levels of serum PLA2R anti-body (P = 0.004), increased proteinuria (P = 0.008), lower serum albumin (P = 0.019), more prominent chronic pathological lesions in terms of glomerulosclerosis score (P = 0.025), interstitial fibrosis score (P = 0.016), tubular atrophy score (P = 0.010) and total renal chronicity score (P = 0.010), and were more likely to be accompanied by focal segmental glomerulosclerosis (P = 0.014). Higher SAb level was associated with the total renal chronicity score (odds ratio per 100 RU/mL, 1.16; 95% confidence interval 1.01-1.33; P = 0.033). Conclusions. PLA2R-associated MN patients with seropositive PLA2R antibody but negative PLA2R deposits in the glomeruli by IF-F have higher levels of SAb and worse clinicopathological manifestations compared with their double-positive counterparts. IHC-P can be an alternative technique to reveal PLA2R glomerular deposits.
引用
收藏
页码:2216 / 2223
页数:8
相关论文
共 50 条
[41]   Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis [J].
Garcia-Vives, E. ;
Sole, C. ;
Moline, T. ;
Alvarez-Rios, A. M. ;
Vidal, M. ;
Agraz, I. ;
Ordi-Ros, J. ;
Cortes-Hernandez, J. .
LUPUS, 2019, 28 (03) :396-405
[42]   Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain [J].
Fresquet, M. ;
Rhoden, S. J. ;
Jowitt, T. A. ;
McKenzie, E. A. ;
Roberts, I. ;
Lennon, R. ;
Brenchley, P. E. .
JOURNAL OF AUTOIMMUNITY, 2020, 106
[43]   Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy [J].
Cravedi, Paolo ;
Ruggenenti, Piero ;
Remuzzi, Giuseppe .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (08) :1400-1402
[44]   Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role [J].
Liu, Wenbin ;
Gao, Chang ;
Dai, Haoran ;
Zheng, Yang ;
Dong, Zhaocheng ;
Gao, Yu ;
Liu, Fei ;
Zhang, Zihan ;
Liu, Zhiyuan ;
Liu, Weijing ;
Liu, Baoli ;
Liu, Qingquan ;
Shi, Jialan .
FRONTIERS IN IMMUNOLOGY, 2019, 10 :1809
[45]   New physiopathological roles for the PLA2R1 receptor in cancer and membranous nephropathy [J].
Girard, Christophe A. ;
Seitz-Polski, Barbara ;
Dolla, Guillaume ;
Augert, Arnaud ;
Vindrieux, David ;
Bernard, David ;
Lambeau, Gerard .
M S-MEDECINE SCIENCES, 2014, 30 (05) :519-525
[46]   Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab [J].
Schmidt, Tilman ;
Schulze, Matthias ;
Harendza, Sigrid ;
Hoxha, Elion .
JOURNAL OF NEPHROLOGY, 2021, 34 (02) :603-606
[47]   The Diagnosis Accuracy of PLA2R-AB in the Diagnosis of Idiopathic Membranous Nephropathy: A Meta-Analysis [J].
Du, Yu ;
Li, Junhua ;
He, Fan ;
Lv, Yongman ;
Liu, Wei ;
Wu, Ping ;
Huang, Jiao ;
Wei, Sheng ;
Gao, Hongyu .
PLOS ONE, 2014, 9 (08)
[48]   Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence [J].
Destere, Alexandre ;
Teisseyre, Maxime ;
Merino, Diane ;
Cremoni, Marion ;
Gerard, Alexandre ;
Crepin, Thomas ;
Jourde-Chiche, Noemie ;
Graca, Daisy ;
Brglez, Vesna ;
Benzaken, Sylvia ;
Esnault, Vincent L. M. ;
Benito, Sylvain ;
Drici, Milou -Daniel ;
Seitz-Polski, Barbara .
KIDNEY INTERNATIONAL REPORTS, 2024, 9 (01) :134-144
[49]   Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN) [J].
Radice, Antonella ;
Trezzi, Barbara ;
Maggiore, Umberto ;
Pregnolato, Francesca ;
Stellato, Tiziana ;
Napodano, Pietro ;
Rolla, Davide ;
Pesce, Gianpaola ;
D'Amico, Marco ;
Santoro, Domenico ;
Londrino, Francesco ;
Ravera, Federica ;
Ortisi, Giuseppe ;
Sinico, Renato Alberto .
AUTOIMMUNITY REVIEWS, 2016, 15 (02) :146-154
[50]   Phospholipase A2 Receptor (PLA2R1) Sequence Variants in Idiopathic Membranous Nephropathy [J].
Coenen, Marieke J. H. ;
Hofstra, Julia M. ;
Debiec, Hanna ;
Stanescu, Horia C. ;
Medlar, Alan J. ;
Stengel, Benedicte ;
Boland-Auge, Anne ;
Groothuismink, Johanne M. ;
Bockenhauer, Detlef ;
Powis, Steve H. ;
Mathieson, Peter W. ;
Brenchley, Paul E. ;
Kleta, Robert ;
Wetzels, Jack F. M. ;
Ronco, Pierre .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (04) :677-683